What This Means for Our Practice Seven additional Phase 3 trials are expected in 2026, evaluating retatrutide across obesity, type 2 diabetes, sleep apnea, chronic low back pain, and MASLD
Every lot is independently tested for identity, purity, and content, with a lot-specific Certificate of Analysis available for review
In the UK, NICE (the National Institute for Health and Care Excellence) would subsequently evaluate the clinical and cost-effectiveness of retatrutide before recommending whether it should be made available on the NHS
doi: 10.1016/j.jval.2017.11.014
Nausea Diarrhea Vomiting Constipation It should be understood that there is no long-term data, as even Ozempic has only been on the market for about 8 years
Limited data exists for: Understudied Populations: Adults over 75 years (increased sensitivity to appetite suppression) Adolescents (ongoing development considerations) Individuals with BMI under 27 (insufficient safety data) Pregnant or lactating individuals (no safety data) Individuals with significant psychiatric conditions Gender Considerations: Research suggests some metabolic peptides may show differential effects between males and females, though data for cagrilintide and retatrutide specifically remains limited
